INTRODUCTION
Friedreich ataxia (FRDA) is an autosomal recessive hereditary disease, affecting 1 person in 29,000, due to a mutation of the FXN gene located on chromosome 9. [1] [2] [3] The major observed mutation is a GAA repeat expansion in the intron 1, 4-6 which causes transcriptional silencing due to the formation during RNA elongation of abnormal structures between DNA and RNA at the site of GAA repeats in intron 1, due to different DNA epigenetic changes (such as DNA methylation and histone modifications), and due to heterochromatin formation (by hypoacetylation of histones, mainly histones 3 and 4, and trimethylation of histone 3 lysine 9). 4, 5, 7, 8 As a result, the promoter becomes inaccessible to transcription factors, leading to a severe deficiency of transcriptional initiation in FRDA, 9 ,10 which leads to a decrease of the frataxin protein to as low as 4%-29% of normal cell level. 2, 4, 11, 12 Frataxin is a 14-kDa mitochondrial protein 2, 13 that plays an important role in iron metabolism and in electron transport by iron-sulfur complexes. 2, 5, 13 The reduced frataxin expression causes abnormal functioning of mitochondrial enzymes, such as aconitase, 14, 15 and perturbation of the iron-sulfur complex biosynthesis. This results in free iron accumulation in mitochondria and increased reactive oxygen species (ROS) production that induces oxidative stress and damage in cells. 1 These disturbances result in several of the most striking symptoms of FRDA, which are disorders of movement coordination, neurodegeneration, a cardiomyopathy, dysregulation of blood glucose with diabetes mellitus, optic atrophy, hearing loss, and sleep apnea. 2, 5, 13, 16, 17 These symptoms appear between 10 and 15 years of age and lead to the eventual confinement to a wheelchair, 4 and the average age of death was at 37.5 years. 13, 18 There is currently no curative treatment for FRDA, however, several potential treatments are in development. [19] [20] [21] The aim of these potential treatments is to reduce and manage symptoms and slow down the progression of the disease. Our project aimed to increase the expression of frataxin by targeting the promoter with TALE (Transcription Activator-Like Effector) proteins fused with a transcriptional activator (TA) VP64 or p300. The latter recruit transcription factors that allow chromatin remodeling, and the promoter becomes more accessible to transcription factors after epigenetic changes and euchromatin formation. The recruitment of RNA polymerase and initiation of transcription of the FXN gene are also increased. [22] [23] [24] [25] TALEs are DNA-binding proteins that contain repeated blocks of 34 amino acids. Two amino acids in positions 12 and 13, called Repeat Variable Diresidues (RVDs), determine which nucleotide is bound by this part of the TALE protein. 26, 27 Platinum TALEs contain additional modifications of the amino acids in positions 4 and 30 of the 34 amino acid blocks. 28, 29 These modifications were reported to increase their DNA-binding affinity. 28, 29 TALE proteins were fused with a TA (e.g., VP64 or p300) or with a peptide containing 10 or 24 SunTag (ST) epitopes, each allowing the recruitment of one scFv-VP64 to activate the expression of a specific gene. 24, [30] [31] [32] We have, therefore, produced several platinum TALE-TAs (plTALE VP64s , plTALE p300s , plTALE ST10Xs , and plTALE ST24Xs ) targeting sequences of 13 or 15 nt in the FXN promoter or in intron 1 to activate the expression of that gene. Some of the targeted sequences are the binding sites for transcription factors. The advantage of targeting a longer nucleotide sequence is a potential reduction of off-target effects and an increase in the effectiveness. 33 Our therapeutic approach was tested in vitro in fibroblasts from different FRDA patients by nucleofecting plasmids expressing a plTALE VP64 or a plTALE ST under a cytomegalovirus (CMV) or a CMV early enhancer/chicken b-actin (CAG) promoter. We have also tested the efficacy of the best plTALE VP64s and plTALE ST10X in vivo by intraperitoneal (i.p.) delivering with an AAV9 [34] [35] [36] to YG8R mice, an FRDA model. [37] [38] [39] These effectors increased the expression of frataxin up to 10-fold in the heart and up to 35-fold in the muscles of treated mice. The development of this technology may also be useful to increase gene expression in other hereditary diseases.
RESULTS

Induction of the FXN Gene In Vitro in FRDA Fibroblasts with plTALE VP64s
We initially constructed 14 plTALE VP64s in vector pCR3. and 1B). We targeted specific sequences of the FXN gene regulatory region and the initiation of the transcription, located up to 220 nt upstream of the ATG site ( Figure 1C) . One of the target sequences (F4) was located at 234 nt downstream of the ATG in intron 1, overlapping the EGR3 binding site ( Figure 1C ). Thus, some of the targeted sequences fixed a transcription factor (TFRAP2, SP1, and EGR3; Figure 1C ) and others did not. The targeted sequences always started with a 5 0 thymidine (T) and were 13 or 15 nt in size, respectively, for plTALE with 13 or 15 RVDs. The number of RVDs may increase the binding efficiency to the target sequence and the efficiency of transcription induction, and it may reduce off-target effects. 33 The efficacy of each plTALE VP64 was tested on FRDA4078 primary fibroblasts (derived from a Friedreich patient with 541/420 GAA repeats) by nucleofection using the same parameters as for the GFP control (the plasmid L6V5 of 9,400 pb) ( Figure S1C ). These in vitro treatments were intended to measure the activity of these effectors on the increase of transcription and expression of frataxin in FRDA4078 cells 3 days after the nucleofection compared to two negative controls. These controls were cells nucleofected only with the nucleofection solution or cells nucleofected with the empty pCR3.1 vector that did not express a plTALE. The plTALE VP64 activities were measured by quantifying the number of FXN mRNAs per microgram of total RNA extracted from the FRDA4078 cells (Figure 2A ). The FXN mRNA results were normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs ( Figure 2B ). The plTALE VP64s containing 13 RVDs that targeted the sequences 1, 2, 3, 7, F2, 11, and F3 did not increase the FXN gene expression of FRDA4078 cells compared to the negative controls. The plTALE VP64s , which targeted the sequences 6, 7, and 8 located between the binding sites of the transcription factors SFR and TFAP2, increased the FXN gene expression more than other plTALE VP64s that targeted the FXN promoter (Figures 2A and 2B ). The plTALE VP64s targeting sequences 6 and 8 increased expression by up to 2-fold (****p < 0.0001). The plTALE VP64 , which targeted the F4 sequence, increased FXN mRNA in FRDA4078 cells by more than 2-fold (****p < 0.0001). Thus, plTALE VP64 effectors activated up to 2.5-fold the endogenous FXN gene in FRDA cells depending on the target sequence and the number of RVDs. The plTALEs with 15 RVDs were more effective than plTALEs with 13 RVDs that targeted the same sequences of the regulatory regions of the FXN gene (Figures 2A and 2B ).
The efficacy of the 3 best plTALE VP64 (plTALE [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , plTALE [8] [9] [10] [11] [12] [13] [14] [15] , and plTALE F4-15 ) to increase the transcription of the FXN gene in the FRDA4078 cells was tested ten times (n = 10, ****p < 0.0001) and compared with the negative controls ( Figure 2C ). The results showed that the 3 plTALE VP64s induced the transcriptional activity of the FXN gene with only small efficiency variations. These 3 effectors also increased by 2.5-to 2.7-fold relative to the negative controls the expression of the frataxin protein normalized with GAPDH protein (Figures 2D and 2E) . We subsequently made new plTALEs fused with a 10Â ST or 24Â ST (plTALE ST10Xs or plTALE ST24Xs ) ( Figure 3A) , which can recruit 10 or 24 scFv-sfGFP-VP64-GB1 (scFv) ( Figure 3B ) to further improve the transcription of the endogenous FXN gene in FRDA cells.
The FXN transcription induced by the 12 plTALE STs in FRDA4078 was normalized with GAPDH or hypoxanthine phosphoribosyltransferase (HPRT) mRNAs and compared to the negative controls (the untreated cells and the cells treated with the vector expressing scFv and the empty vector pCR3.1) ( Figure 3C ). The plTALE ST10Xs (containing 10 STs) were more effective at increasing frataxin expression than plTALE ST24Xs (containing 24 STs) targeting the same sequence ( Figure 3C ; see also Figure S4 ). Indeed plTALE and plTALE (containing 24 STs and 15 RVDs and targeting, respectively, sequences 6 and 8) increased significantly FXN transcription in FRDA4078 cells by about 2-fold ( Figure 3C , left panels), whereas plTALE ST10X-6-15 and plTALE ST10X-8-15 significantly increased FXN transcription by 4-to 5-fold ( Figure 3C , right panels). These results also confirmed that plTALE ST10Xs containing 15 RVDs were more effective than those containing 13 RVDs. The two best plTALE ST10Xs (plTALE ST10X-6-15 and plTALE ) also increased the expression of the frataxin protein in FRDA4078 cells 2 days after the treatment by about 3-fold ( Figures 3D and 3E) . None of the plTALE ST24Xs and the plTALE ST10X-10-13 increased expression of the frataxin in FRDA4078 cells ( Figures 3D and 3E ).
FRDA4078 cells were treated with 2 plTALE ST10X together containing either 13 or 15 RVDs targeting sequences 6 and 8 ( Figures 4A and 4B ). The 2 plTALE ST10Xs containing 13 RVDs increased FXN transcription about 3-fold, whereas the two plTALE ST10Xs containing 15 RVDs had a stronger synergic effect and increased FXN transcription more than 11-fold (****p < 0.0001), resulting in a 5-fold increase of the frataxin protein ( Figures 3D and 3E) . Thus, the combination of two plTALE ST10Xs with 15 RVDs targeting sequences 6 and 8, which are separated by 10 nt, recruited up to 20 VP64s at those target regions located between the SFR and TFAP2 sites, resulting in a strong transcription activity of the FXN gene.
Reversible modulation of aconitase has been used as a biomarker of FRDA oxidative stress; 40, 41 the aconitase activity may thus be used as an indicator of the activity of frataxin in the mitochondria. The activity of aconitase was measured in cells treated with plTALE ST10X-6-15 plus plTALE together and negative controls (untreated cells and cells treated with pCR3.1-scFv plus pCR3.1 empty) ( Figure 4C ). The aconitase activity was increased significantly by more than 2.2-fold in the cells treated with these effectors compared to the negative controls (n = 3, *p = 0.03). Thus, these results indicated that the increase in transcription of the endogenous FXN gene and the resulting expression of the frataxin protein in the cells treated with the plTALE ST10Xs increased aconitase activity. Therefore, they strongly suggest that plTALE ST10Xs can correct the molecular and biochemical symptoms of FRDA. The activity of each plTALE VP64 on each FRDA cell type was normalized with GAPDH or HPRT mRNAs and compared to 2 negative controls (untreated cells and cells treated with an empty vector pCR3.1) ( Figure 5 ). We detected significant positive effects in the 4 FRDA cell types treated with the 3 plTALE VP64s . The treatment increased the number of copies of FXN mRNA approximately 2-fold in the 4 FRDA cell types ( Figure 5A ). The transcriptional activity of frataxin was normalized with GAPDH or HPRT mRNAs, and an increase of about 1.7-to 2. 6C ) about 3.5-fold. These 2 effectors had a synergic effect and increased by 12-fold FXN expression. These results showed that plTALE ST10X-6-15 and plTALE were effective even in cells (FRDA162, FRDA4675, and FRDA4743) with a large number of GAA repeats and, thus, with a low frataxin expression.
Proteins from 4 different FRDA patient cells were analyzed by western blots after treatment with plTALE ST10X (Figures 6D and 6E). PlTALE ST10X-6-15 and plTALEs alone increased the frataxin protein by 7.5-and 9.7-fold, respectively, in FRDA66 and by 3-to 4.8-fold in FRDA162, FRDA4675, and FRDA4743. Frataxin expression was much stronger with the synergistic effect of these two effectors in the FRDA66 and FRDA4675 cells, the increase in fact exceeding 12-fold. In conclusion, the strong activation of the transcription of the FXN gene of the FRDA cells having different numbers of GAA repeats also increased the expression of the frataxin protein in these cells treated by these effectors.
These results clearly indicated that plTALE VP64 and plTALE ST effectors that target specific sequences can activate the transcription of the endogenous FXN gene as well as the expression of the frataxin protein of the treated cells. 
Induction of the FXN Gene In Vivo in YG8R
Mice by plTALE VP64 Effectors
The 3 best plTALE VP64s (i.e., plTALE [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , plTALE [8] [9] [10] [11] [12] [13] [14] [15] , and plTALE F4-15 ) were tested in vivo in YG8R mice, [37] [38] [39] an FRDA model. The mice were injected i.p. between 7 and 11 days of age with doses of AAV9-plTALE VP64 ranging from 6 Â 10 11 and 18 Â 10 11 viral particles (v.p.). The negative controls were YG8R mice not treated or treated with an AAV9 not expressing the plTALE VP64 (AAV-Ctrl). During treatment, the body weight of the treated mice was similar to the body weight of the untreated mice ( Figure S5 ). The mice were sacrificed 1 month after injection of the AAV9 to verify the effects of these AAV9-plTALE VP64s on the activation of the FXN gene. RNA, DNA, and proteins were extracted from different tissues (muscles, heart, liver, and brain).
The presence of the virus was detected by qPCR in all tested tissues (muscles, heart, liver, and brain) but predominantly in the heart (Figure S6A, left) . No virus was detected in the untreated YG8R mice. The amount of viral genome detecetd varied proportionally to the dose of injected AAV9 expressing the plTALE VP64 . The distribution of AAV9-plTALE VP64s in the different organs influenced the expression of plTALE VP64 effectors in these organs ( Figure S6B ). A higher expression was detected in the heart ( Figure S6B , left) than in the other organs ( Figure S6B on the right). However, the plTALE VP64 expression depended not only on the amount of virus present in the organ but also on the nature of the organ. Indeed, in the liver, the number of v.p. detected was similar to that in the muscle (Figure S6A, right) , but the TALE expression was 10-fold higher in the muscle than in the liver ( Figure S6B , right).
A 2-fold significant increase of transcriptional activity of the FXN gene was observed in the heart of mice injected with 6 Â 1011 or 18 Â 10 11 AAV9-plTALE VP64-8 ( Figure 7A ). A small non-significant increase was also detected with the AAV9, which expressed plTALE VP64-F4 , compared to untreated mice. In the muscles of the mice treated with AAV9-plTALE VP64 , the transcriptional activity was significantly increased with AAV9-plTALE VP64-8 by approximately 2-fold with the 18 Â 10 11 dose and 1.5-fold with the 6 Â 10 11 dose compared to negative controls. Transcription of the FXN gene was also increased in the muscles of mice treated with 6 Â 10 11 or 18 Â 10 11 AAV9-plTALE VP64-6 , respectively, by 1.4-and 1.7-fold (significant increases). In contrast, the transcriptional activity of the FXN gene did not change in the liver and in the brain of mice treated with most of the AAV9-plTALE VP64s . However, a small increase in transcription of the FXN gene was observed in the liver of the mice treated with AAV9-plTALE VP64-8 and in the brain of the mice treated with AAV9-plTALE VP64-6 (18 Â 10 11 v.p.). These results strongly suggest that the variation in virus distribution from one organ to another affected the expression of plTALE VP64 effectors but the tissue specificity also affected the expression.
The increase in the expression of the frataxin protein in these organs also depended on the increase in the transcription of the FXN gene ( Figure 7B ). In the heart, the expression of frataxin was increased 2.4-fold (significant) and 1.8-fold (not significant) with AAV9-plTALE VP64-6 with the doses 6 Â 10 11 and 18 Â 10 11 v.p., respectively. Increases of 2-fold (not significant) and 2.1-fold (significant) were obtained with AAV9-plTALE VP64-8 at doses of 6 Â 10 11 and 18 Â 10 11 compared to the untreated mice. In the muscles of the treated mice, the quantity of frataxin protein was increased by 2-fold and 4.6-fold with AAV9-plTALE VP64-8 of the doses 6 Â 10 11 and 18 Â 10 11 and by 1.5-fold and 3.5-fold with AAV9-plTALE VP64-6 of the doses 6 Â 10 11 and 18 Â 10 11 v.p., respectively. The increases with the higher dose (18 Â 10 11 v.p.) were significant compared to the untreated mice. The frataxin protein did not increase in other organs (liver and brain).
Induction of the Human FXN Gene in the YG8R Mice with plTALE ST10Xs
The efficacy of the best plTALE ST10Xs was tested in vivo in YG8R mice. The mice were injected i.p. either with AAV9-plTALE ST10X-6 + AAV9-scFv, with AAV9-plTALE ST10X-8 + AAV9-scFv or with AAV9-plTALE ST10X-6 + AAV9-plTALE ST10X-8 + AAV9-scFv. We used doses of 1. The fluorescent label distribution in the treated mice was compared with the negative controls, i.e., untreated mice and mice treated with AAV9-scFv and an AAV9 that did not express a plTALEs ST10X (named CtrlÀ). The confocal image of the tissues (muscles and heart) of treated mice with the AAV9s expressing a plTALE ST and an scFv showed the location of the sfGFP fluorescence in the nuclei ( Figures S7A and S7B ). The intensity of the sfGFP fluorescence was much brighter in the nuclei of tissues treated with AAV9
expressing the scFv-sfGFP-VP64 (scFv) and the effectors plTALE ST10X-6 and plTALE ST10X-8 than in tissues expressing only the scFv. These two plTALE STs were able to recruit together up to 20 scFv, thereafter allowing the localization of the fluorescent label (scFv-sfGFP-VP64) complexes in target sites in the FXN gene promoter.
The detection of virus particles was made in different organs: muscles, heart, liver, and brain. Both viruses were detected, i.e., the one containing the sfGFP ( Figure S8A ) and the one containing the plTALE ST (Figure S8B) . For both viruses, more copies were detected in the heart than in the other organs ( Figures S8A and S8B ). Fewer viruses were detected in the brain probably in part due to the blood-brain barrier. The expressions of sfGFP ( Figure S8C ) and of plTALE ST ( Figure S8D ) were both higher in the heart, followed by the muscle, and again the lowest in the brain. The transcriptional activity of the FXN gene in the muscle, and in the heart of mice treated with a single plTALE ST10X or with the combination of the two plTALE ST10Xs together, was strongly activated ( Figure 8A ). The transcriptional activity increased in mice treated with the plTALE ST10X-6 or with the plTALE ST10X-8 by 5.7-and 5.3-fold, respectively, in the muscles and by 2-to 3.5-fold in the heart. The combination of two different plTALE ST10Xs (3 Â 10 11 v.p. of plTALE ST10X-6 + 3 Â 10 11 v.p. of plTALE ST10X-8 ) produced additive significant effects on the transcription of the FXN gene, and it resulted in an 11.8-fold increase in the muscle and a 5.5-fold increase in the heart compared to the negative controls. The in vivo synergistic effect of AAV9-plTALE ST-6 (1.5 Â 10 11 v.p.) and AAV9-plTALE ST-8 (1.5 Â 10 11 v.p.) significantly increased transcription by 21.6-fold in the muscles and by 4.5-fold in the heart of the treated YG8R mice. There was only a small increase of transcription in the liver and no effect in the brain. Strong increases of the frataxin protein were observed in the muscles and the heart of mice treated with these plTALE ST10Xs compared to the negative controls ( Figure 8B ). These increases were 8-fold and 3.3-fold in the muscles and 2.8-to 3.5-fold in the heart of mice treated with plTALE ST10X-6 or with plTALE ST10-8 , respectively. An additive effect was observed when both effectors (i.e., AAV9-plTALE and AAV9-plTALE ST-8 ) were used together; the increase reached 15-fold in the muscle and 6-fold (significant) in the heart. In the liver, a significant increase was also detected, ranging between 2.4-and 3-fold compared to the untreated mice. However, the synergistic effect of these 2 effectors significantly www.moleculartherapy.org increased the expression of frataxin protein by 35-fold in the muscles, 10-fold in the heart, 3-fold in the liver, and 2-fold in the brain (Figure 8B) . These strong inductions of the expression of frataxin with the synergistic effect increased the activity of the aconitase in the heart of the treated mice compared with the untreated mice ( Figure 8C ). This induction of the FXN gene makes it possible to regulate the expression of the other genes, e.g., PGC-1a and GAD65, which are necessary for mitochondrial biogenesis. Expression of these genes is regulated with the level of expression of the frataxin protein in cells. 42 The expression of PGC-1a was increased ( Figures 9B and 9E ) when the expression of frataxin increased ( Figures 9A and 9D ) in mice treated with AAV9-plTALE ST10X . This increase was significant in the muscles (Figure 9B ) of the treated mice, but not in the heart (Figure 9E) . FXN gene activation decreased the expression of the GAD65 gene significantly ( Figure 9C ) in the muscles of the treated mice, and the increase did not reach a significant level in the heart ( Figure 9D ). These results strongly suggest that the plTALE ST10X system can restore FRDA phenotypes in vivo in FRDA model mice. This encourages us to continue the development of this plTALE TA system to aleviate cardiac and neurological FRDA symptoms.
DISCUSSION
The improved understanding of the FRDA molecular pathogenesis 4,5,7-10,43 and the TALE technology development [22] [23] [24] [25] 27, 28 have both contributed to the development of our proposed therapeutic approach, which aims to activate the transcription initiation of the FXN gene to restore the normal mitochondrial function in FRDA cells.
TALEs are DNA-binding proteins that can be fused with a TA, such as VP64 or p300, to increase endogenous gene expression by the activation of transcription initiation of the target gene. 24, 25, 31, 44 This approach has been used to induce the activation of the Oct4 (Pou5f1), 31 IL1RN, MYOD, and OCT4 genes 24 and to reactivate the latent HIV-1 provirus. 30 We used plTALEs that are easier to construct and have a higher specificity and affinity toward their target sequences than normal The FXN gene was induced in mice treated with AAV9, which expressed either the plTALE [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These results showed that the initiation of transcription is very strong at sites 6 and 8. This induced chromatin remodeling and promoter activation after epigenetic change through the recruitment of transcription complexes by plTALE VP64 .
22-25
The plTALEs fused with p300-targeting sequences 6, 8, and F4 were less effective than plTALEs fused with VP64 targeting the same sequences ( Figure S2D ), thus confirming the results of Hilton et al. 24 for IL1RN, MYOD, and OCT4 genes. Anthony et al. 47 reported a synergistic effect when a TALE fused with the TATA-box-binding protein (TBP-TALE) and a TALE VP64 were used together for the activation of the IL-2 gene in 293T cells. However, in our experiments, the combination of the plTALE VP64 and plTALE p300 did not produce a synergistic effect on FXN gene transcription ( Figure S2E ).
Treatment of FRDA4078 cells with two p1TALE p300s targeting sequences 6-15 and 8-15 increased the transcription and expression of the FXN gene by about 2-fold ( Figures S3A and S3B ). This result is the equivalent of the effect of a single plTALE VP64 targeting sequences 6-15, 8-15, or F4-15 . This suggests that the acetylation of chromatin by the p300 activator only occurs when the target sequences are far away from the transcription initiation site. Our results confirm those of Hu et al., 31 who targeted the Oct4 gene enhancer region with p300. However, the high methylation of the FRDA FXN gene can be a major obstacle to acetylation of this gene by p300. Xu et al. 48 have used a DNA demethylase (dCas9-MS2-Tet1-CD) to resolve a similar gene-silencing problem.
Ji et al. 49 showed in vitro activation of the HIV-1 LTR promoter with a dCas9-ST24X. We thus used the plTALE ST system to further increase the transcription activity of VP64 on the endogenous FXN gene. An ST fused with a single plTALE permits recruitment of 10 or 24 VP64s at the regulatory region of the FXN gene. Our results showed that a single plTALE ST10X induced a stronger expression of the endogenous FXN gene than a plTALE VP64 . A similar observation was made by Tanenbaum et al. 32 with a dCas9 protein fused with an ST and a guide RNA (gRNA) targeting the promoter of the CDKN1B gene. However, the plTALE ST24X and some plTALE ST10X targeting non-active promoter sequences or the EGR3 binding sequence did not increase the FXN gene expression. Moreover, the synergistic effect of these effectors plTALE ST10X reactivated the endogenous FXN gene in FRDA cells even more strongly compared to the effect of a single plTALE ST10X . In fact, a single plTALE ST10X targeting sequence 6-15 or sequence 8-15 induced the transcription initiation of the FXN gene after recruitment of the transcriptional complex by several VP64s (10 VP64 for plTALE ST10X ). 24, 25, 27, 31, 50 Two plTALE ST10Xs targeting two active regions of the transcription initiation site recruited a total of 20 VP64s, allowing a powerful activation of the endogenous FXN gene.
The plTALE containing 15 RVDs induced a higher FXN expression than the plTALE containing 13 RVDs, which targeted the same sequences. This may be because the higher number of RVDs increased the specificity and the affinity of the plTALE proteins for their DNA target sequences. Our results confirm those of Rinaldi et al. 33 Figure 8. Induction of the FXN Gene In Vivo in YG8R Mice Treated with AAV9 Expressing the plTALE ST10X-6-15 or plTALE and AAV9 Expressing scFV-GFP-VP64 Mice were treated with two AAV9s (one containing scFV and the other one plTALE or plTALE ). To test potential synergistic effects of the combination of these two effectors, three AAV9 were used (AAV9-scFV, AAV9-plTALE ST10X-6-15 , and AAV-plTALE ). Several tissues were analyzed (muscle, heart, liver, and brain) in the treated mice and compared to those of control YG8R mice: untreated or treated with an AAV9, Ctrl (À), that did not express plTALE ST10X . (A) Quantification of the number of FXN mRNAs by qRT-PCR in various organs of 3 different types of control mice and 4 groups of mice treated with the plTALE ST10Xs . Additive and synergic effects were observed in muscles and heart when plTA-LE ST10X-6 and plTALE ST-10X-8 were used together. (B) The frataxin protein was significantly increased in muscle, heart, and liver of mice that received various plTALE ST10X treatments. (C) Increased aconitase activity in the hearts of mice treated with AAV9-plTALE ST10X-6-15 + AAV9-plTALE ST10X-8-15 + pAAV-scFv plasmids. This increase is relative to negative controls (untreated mice) (n = 4). *p < 0.05, **p < 0.003, ***p < 0.0003, and ****p < 0.0001. (A-C) Results are the average ± SEM.
The efficacies of the best plTALE VP64s and plTALE ST10Xs , as potential FRDA treatments, were investigated in fibroblasts of four FRDA patients containing different numbers of GAA repeats. Our results showed that the 3 best plTALE VP64s activated transcription in all FRDA cells, even in cells with a large number of GAA repeats (355/805 and 470/970). A strong synergistic increase of the FXN mRNA and of the frataxin protein was obtained when two effectors (plTALE ST10-6-15 and plTALE ) were used. Thus, plTALE ST10Xs are powerful effectors to increase the expression of the endogenous FXN gene in FRDA cells. These results demonstrate that the effector plTALE TA activates transcription initiation in the case of FRDA regardless of the number of GAA in intron 1. This is strongly suggestive that the development of a gene therapy with plTALE TA is, therefore, an effective strategy for treating this anomaly by targeting the main cause, namely, silencing the gene and decreasing the expression of frataxin.
We conducted in vivo experiments with the best plTALE VP64 and plTALE ST in the YG8R mouse model of FRDA. 37, 51 These effectors were delivered i.p. with AAV9s, which is the most frequently used vector for gene therapy. 35, 36, [52] [53] [54] These effectors were under a CAG promoter 55 permitting expression in most mouse tissues, 56, 57 including the brain, heart, liver, and muscles, which are mainly involved in FRDA. 13 Following i.p. injection, the AAV9 distribution varied from organ to organ and was stronger in the heart, muscles, and liver than in the brain, confirming the previous results of our www.moleculartherapy.org group in 2014 and 2016. 34, 58 A strong heart infection was also observed by Carroll et al. 59 and Mayra et al. 36 Although AAV9 is able to cross the blood-brain barrier, the delivery to the brain was low in our experiments. 60 The amount of virus in each organ proportionally influenced the expression of plTALE VP64 and plTALE ST . Thus, we observed a higher increase of FXN transcription by plTAL-E ST-6 and plTALE in muscles and heart and no effect in the YG8R brain. Therefore, our results showed for the first time that TALE ST can increase the expression of an endogenous FXN gene in vivo.
The increase of the FRDA FXN gene expression in vitro and in vivo by plTALE ST10X-6-15 and plTALE ST10X-8-15 improved mitochondrial activity in FRDA cells as indicated by the increased aconitase activity and regulation of PGC-1a and CAD65. 42 Khonsari et al. 15 also observed a 2-fold increase of the aconitase activity in FRDA fibroblasts treated in vitro with lentiviruses expressing the frataxin protein.
Given our positive in vivo results, we now plan to test the plTALE effectors in the YG8sR mouse, a new FRDA model containing 300 GAA repeats. 38 Given that the AAV9 did not induce an increased FXN expression in the brain, there are new AAV serotypes such as AAV-PHP.eB, which have been recently described to better deliver genes to the brain; 61 we will test this new serotype. These tests will enable us to validate the in vivo effectiveness of the plTALEs to treat a FRDA mouse model before clinical trials. PGC-1a (B) , and GAD65 proteins (C) in the muscles of mice treated with AAV9-pTALE-ST10X-6 + AAV9-plTALE ST10-8 + AAV9-scFv compared to untreated mice. (D and E) The levels of expression of frataxin and GAD65 (D) and PGC-1a proteins (E) in the heart of mice, which received the same treatment compared to untreated mice. *p < 0.05, **p < 0.003, ***p < 0.0003, and ****p < 0.0001. (A-E) Results are the average ± SEM.
Could the two plTALE ST , which best increased frataxin expression, also increase the expression of other genes? To induce expression of an offtarget gene, the plTALE ST would need to bind to an off-target sequence, which is in a promoter (not any genomic sequence as is the case for offtarget mutations induced by TALE nucleases [TALENs] or by an active Cas9). Our experiments demonstrated that, even when some plTALE-VP64 or plTALE ST bind to a promoter region of a gene, they do not necessary induced gene expression. Indeed as illustrated in our Figure 1C , we have made several plTALE-VP64 targeting other sequences in the frataxin promoter (sequences 1, 2, 3, 11, F2, F3, and F4) and several plTALE ST targeting sequences (7, 10, and F4), which did NOT induce frataxin expression. Moreover, plTALE ST targeting shorter nucleotide sequences (i.e., 13 instead of 15 nt, sequences 6-13, 7-13, and 10-13 in Figure 3C ) did NOT increase frataxin expression. Thus, the probability of inducing an off-target gene by our plTALE-ST10X-6-15 or plTALE-ST10X-8-15 is very low. However, for an eventual clinical application, studies of the off-target effects of the plTALEs using RNA sequencing (RNA-seq) and of the immune responses against the effectors may be required by the regulatory agencies.
In summary, our results showed that transcription activation by plTALE ST is a promising approach to treat FRDA by increasing the expression of the endogenous FXN gene. This approach may have several advantages over other therapeutic approaches. It may produce fewer off-target effects than genome editing with CRISPR or TALEN. This plTALE VP64 and plTALE ST therapeutic approach may also be used for many other hereditary diseases due to haploinsufficiency.
MATERIALS AND METHODS
DNA Constructs
We used the Platinum TALEN kit (Kit 1000000043, Addgene, Cambridge, MA, USA) 28 to construct pCR3.1-plTALE TAs . This kit contains 34 plasmids distributed as follows: 16 plasmids containing the various RVD modules and 8 plasmids containing a single RVD module and the FokI nuclease. In addition, the pFus2 plasmid permits one to group 4 successive RVDs. The FokI nuclease was subsequently replaced by a transcriptional activator.
Platinum TALEs (plTALEs) are distinct from classical TALEs by two particularities. The first one is the variation of amino acids 4 and 30 of the RVD sequences in addition to variations of amino acids 12 and 13 found in conventional TALEs. The second particularity is that the RVDs are assembled using Golden Gate cloning steps with the BsaI enzyme in groups of 2 and 4 RVDs in a plasmid called pFus2 ( Figure S1A ). This technique is very effective compared to the assembly of modules containing 10 RVDs for the TALEN. 28, 62 Three or four pFus2 plasmids each containing 2 or 4 RVDs are subsequently assembled using Golden Gate cloning steps, with the Esp3I enzyme in a single vector ptCMV-VR to obtain a plTALEN (plTALE nuclease) containing 13 or 15 RVDs ( Figure S1B ) 28 and a FokI nuclease. The FokI was subsequently replaced by a transcriptional activator (VP64, p300, or an ST) to construct a plTALE VP64 , plTALE p300 , or plTALE ST in the plasmid pCR3.1. This assembly technique used fewer starting plasmids (p1HD-P4HD, p1NG-p4NG, p1NI-p4NI, and p1NN-p4NN) compared to Golden Gate TALEN and TAL Effector Kit 2.0.
The plTALE ST induction system consists of a plTALE fused with an ST plasmid containing 10 or 24 epitopes (ST10X or ST24X). 32 The latter makes it possible to recruit several VP64 transcriptional activators fused with an scFv peptide (single-chain variable fragment), which is fused with the sfGFP-VP64-GB1 complex. The plTALE ST10X or plTALE ST24X proteins that target the sequences in the FXN gene promoter were expressed by a single pCR3.1-plTALE ST vector. The scFv-sfGFP-VP64-GB1 (scFv) complex was expressed by another vector pCR3.1-scFv-sfGFP-VP64-GB1.
The pAAV-plTALE VP64 , pAAV-plTALE ST10Xs , and pAAV-scFv were first constructed in a pAAV_TALE-TF (VP64)-BB_V3 plasmid (Addgene, 42581, Cambridge, MA, USA). The latter contained a CAG promoter having a similar expression power as the CMV promoter. 26, 28 It also contained an inverted terminal repeat (ITR) sequence at each end. The maximum insert size used in this viral vector was 4,700-bp different FRDA primary fibroblasts.
FRDA Fibroblasts
The plTALE VP64s , plTALE p300s , and plTALE STs were tested in vitro on patient FRDA primary fibroblasts GM04078 (FRDA4078) (obtained from the Coriell Institute, Camden, NJ, USA). These cells contain 541/420 GAA repeats. Subsequently, the best plTALE VP64s and plTALE ST10Xs were tested in vitro on FRDA primary fibroblasts of four different patients: FRDA66 (240/640), FRDA162 (355/805), FRDA4675 (255/1,140), and FRDA4743 (470/970) (generously provided by Dr. Napierala and Dr. Lynch, Children's Hospital of Philadelphia). The results of these tests were compared with the transcriptional activity of the FXN gene in fibroblasts of normal subjects: NED29178, NED36091, NED36320, and NED34769 obtained from the Coriell Institute.
The FRDA and NED cells were grown at 37 C under 5% CO 2 in DMEM (from Wisent, Saint-Jean-Baptiste, QC, Canada) with 10% fetal bovine serum (FBS) (Gibco, Burlington, ON, Canada), 1% antibiotics (penicillin and streptomycin, Gibco by Life Technologies, 15140-122) and 1% Non-Essential Amino Acid 100Â Medium (NEAA, Wisent Bioproducts, 321-011-EL, Canada).
Nucleofection
One million FRDA cells were resuspended in 100 mL nucleofection solution (Amexa nucleofector, ESBE Scientific Products, St-Laurent, QC, Canada) and nucleofected with 10 mg plasmids using the program P022 ( Figure 1F) . 63 The cells were kept in culture for 2 or 3 days with a change of medium every 24 hr, and the expression of frataxin was analyzed by qRT-PCR and western blot.
Western Blot
After RNA extraction with Qiazol, the proteins were precipitated with isopropanol at room temperature (RT) and washed with 0.3 M guanidine hydrochloride and pure ethanol. A resuspension buffer (4% SDS, 0.025 M Tris HCl, 7.5% glycerol, 0.5% b-mercaptoethanol, and bromophenol blue) was used for protein denaturation at 100 C for 5 min. The concentration of proteins was quantified with the Amido black test. 64 Then 25-40 mg protein was separated on a 15% SDS-PAGE gel. Proteins were transferred onto a nitrocellulose membrane (Bio-Rad, Mississauga, ON, Canada).
After blocking, various primary and secondary antibodies were used as follows: anti-frataxin (ab110328, Abcam, Toronto, Canada), anti-GAPDH (Millipore Sigma MAB374, Etobicoke, ON, Canada), and anti-PGC-1a and anti-GAD65 (Thermo Fisher Scientific PA5-38022 and PA5-22260, Rockford, IL, USA). The secondary antibody used was a rabbit anti-mouse and anti-rabbit (Jackson ImmunoResearch, West Grove, PA, USA). After 3 washes in 0.1% PBS and 0.05% Tween for 10 min each, the membrane was revealed using the Clarity Western ECL Substrate kit (Bio-Rad, Mississauga, ON, Canada) and developed to visualize the protein bands. These were quantified with the ImageJ software.
Aconitase Test
Reversible modulation of aconitase was used as a biomarker of FRDA oxidative lesions. Aconitase activity was determined using a coupled enzymatic reaction in which the citrate is converted to isocitrate by the aconitase activity (Aconitase Activity Assay Kit Aconitase activity, Sigma-Aldrich MAK051, St. Louis, MI, USA). One million FRDA4078 cells treated with plTALE ST10X-6-15 + with plTALE ST10X-8-15 or 20-40 mg tissues from mice treated with AAV9-plTALEs TA were lysed in 120 mL test buffer solution. The insoluble material was removed by centrifugation at 800 Â g for 10 min at 4 C. 10 mL aconitase activation solution was added to the cell extract followed by a 1-to 2-hr incubation on ice. 40 mL wholecell lysates was added to the test reaction with and without enzyme mix plus 10 mL test buffer solution. The result of the aconitase activity is a colorimetric product, which was measured at 450 nm absorbance.
In Vivo Tests
Adeno-associated viruses serotype 9 (AAV9) were used to deliver the plTALE TA and induce the expression of the endogenous FXN gene in vivo in YG8R mice. The AAV9 vectors were produced by the Plateforme d'outils moléculaires, Centre de recherche CERVO (Québec, QC, Canada).
The best plTALEs TA were tested in vivo in the YG8R mouse model (The Jackson Laboratory, Sacramento, CA, USA) This transgenic mouse model contains two knockout mouse frataxin allele (Fxn À/À ) and two tandem copies of the human FXN derived from an FRDA patient containing, respectively, about 82 and 190 GAA trinucleotide sequence repeats. [37] [38] [39] The mice were reproduced in the CHUL animal facility, and all experiments were approved by the CRCHUL animal protection committee. YG8R mice were injected i.p. around 7-11 days of age with 1.5, 3, 6, or 18 Â 10 11 virus particles. Their body weight was measured each week. They were sacrificed 1 month later, and tissues (Tibialis anterior muscles, heart, liver, and brain) were recovered, snap frozen in liquid nitrogen, and kept at À80 C until analysis.
RNA Extraction and Quantification of the Expression of TALE, FXN, and GFP
The fibroblast cells or the tissues were homogenized in Qiazol buffer (QIAGEN, Germantown, MD, USA), and total RNA was extracted using the RNeasy mini kit on-column DNase (QIAGEN, Hilden, DE, USA) treatment, following the manufacturer's instructions. Total RNA was measured using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and RNA quality was determined with the Agilent BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). First-strand cDNA synthesis was obtained using 3-4 mg isolated RNA in a reaction containing 200 U Superscript IV Rnase H-RT (Invitrogen Life Technologies, Burlington, ON, CA), 300 ng oligo-dT 18 , 50 ng random hexamers, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 500 mM deoxynucleotide triphosphate, 5 mM dithiothreitol, and 40 U Protector RNase inhibitor (Roche Diagnostics, Indianapolis, IN, USA) in a final volume of 50 mL. The mixture was incubated at 25 C for 10 min and at 50 C for 20 min and inactivated at 80 C for 10 min. A PCR purification kit (QIAGEN, Hilden, DE, USA) was used to purify the cDNA. The cDNA corresponding to 20 ng total RNA was used to perform fluorescent-based real-time PCR quantification using the LightCycler 480 (Roche Diagnostics, Mannheim, DE, USA) and normalized with the expression of GAPDH and/or HPRT1. The qRT-PCR analyses were done by the Plateforme d'Expression Génique of the Centre Génomique du Centre de recherche du CHU de Québec (CRCHUL). The different primers used are listed in Table S1 .
DNA Extraction from Tissues
DNA was extracted from different tissues (muscle, liver, heart, and brain). Briefly, a part of the tissue was recovered incubated with 50 mL proteinase K (10 mg/mL) in a lysis buffer at 56 C until the solution became clear. Digested tissues were then mixed with 500 mL solution of phenol/chloroform/isoamyl alcohol (25:24:1; BioShop Canada) and centrifuged 3 min at 13,000 rpm. The upper solution was recovered and mixed with the same volume of chloroform and centrifuged again. The upper solution was recovered and 50 mL of 5 M sodium chloride was added before the addition of 1 mL 100% ethanol. After centrifugation for 8 min at 12,000 rpm, the pellets were washed in 70% alcohol before another centrifugation. Pellets were dried before DNA suspension in sterile water. A qPCR was made to detect v.p. in the tissues.
Frataxin Protein Quantification with the Dipstick Assay Kit
The protein concentration was estimated using the PierceTM BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). The human frataxin protein was quantified using the Dipstick Array (ab109881, Abcam, Cambridge, MA, USA). A standard curve was also done at the same time with recombinant human frataxin protein ranging from 0.075 to 1.2 ng of frataxin (110353, Abcam, Toronto, ON, Canada) to quantify the frataxin protein in the tissues in nanogram/microgram total protein.
Microscopy
For light microscopy, part of the tissue was incubated with 30% sucrose overnight before including it in Tissue-Tek O.C.T. Compound (Sakura Finetek, Torrance, CA, USA) for freezing in liquid nitrogen. Sections of 12 mm were cut on a Leica CM3050S (Leica Biosystems, Concorde, ON, Canada) and stored at À20 C. The slides were fixed with 10% neutral buffered formalin (Fisher Scientific, Ottawa, ON, Canada) for 10 min before 3 washes of 5 min in PBS. In the second wash, Hoechst 33258 dye (Sigma-Aldrich Canada, Oakville, ON, Canada) was incorporated at 0.2 ng/mL. The slides were mounted with PBS/glycerol and observed by confocal microscopy Leica DMI6000B (GFP: excitation 491 nm, emission 536/40 nm; Dapi Widefield: excitation 350/50, dichroic 400LP, emission 456/50) with an objective 63Â in glycerol immersion (HCX PL APO63X/1, 30Glyc).
Statistical Analyses
The various tests and treatments were carried out several times, with n varying between 2 and 10 times. The results were presented as average ± SEM. Statistical analysis was performed using one-way ANOVA with GraphPad Prism7 software (GraphPad, LaJolla, CA, USA). The p values are indicated in each figure. Statistics: one-way ANOVA was used at 0.05 (95% confidence interval); *p < 0.05, **p < 0.003, ***p < 0.0003, and ****p < 0.0001. 
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